Properties
What is it?
Nimenrix powder and solvent for preparing solution for injection, in a pre-filled syringe Conjugate vaccine against serogroups A, C, W-135 and Y of Neisseria meningitidis Composition: Active substances: After dilution, 1 dose (0.5ml) contains: Neisseria meningitides serogroup A polysaccharide 1–5 micrograms; Neisseria meningitides serogroup C polysaccharide 1–5 micrograms; Neisseria meningitides serogroup W-135 polysaccharide 1–5 micrograms; Neisseria meningitides serogroup Y polysaccharide 1–5 micrograms. 1–44 micrograms conjugated to a carrier protein, tetanus toxoid. Excipients: In the powder: sucrose and trometamol. In the solvent: sodium chloride and water for injections. Indication: Nimenrix is a vaccine that protects the body from infections caused by serogroups A, C, W-135, and Y of the bacterium "Neisseria meningitides". Serogroups A, C, W-135, and Y of "Neisseria meningitides" can cause dangerous diseases such as: meningitis – inflammation of the membranes of the brain and spinal cord. Septicemia – an infectious process spread through the blood. These infections are easily transmitted from person to person and can be fatal without treatment. Nimenrix is used in adults, adolescents, and children from 6 weeks of age. Contraindication: If the patient is allergic to any of the active or excipient substances in the preparation; signs of an allergic reaction may include a rash with itching, difficulty breathing, and swelling of the face or tongue. If these signs develop, the patient should seek medical attention immediately. Warnings and special precautions: Before vaccination, the patient should consult a doctor or nurse: If the patient has an ongoing infection with a high temperature (>38C). In this case, the vaccine will be used only after recovery. A simple infection, e.g., a cold, is usually not a barrier. However, the patient should consult their doctor or nurse if they have any form of infection. If the patient has blood clotting problems or a tendency to bleed. The patient should consult their doctor or nurse before using Nimenrix if any of the above conditions apply to them. Nimenrix may not be equally effective for everyone. For example, in individuals with a weakened immune system (including due to HIV infection or the use of certain medications), Nimenrix may not be sufficiently effective. During any injection with a needle, or before the start of an injection, fainting may occur (mostly in adolescents). Therefore, the patient must inform the doctor if they or their child has ever fainted as a result of an injection procedure. Interactions with other medicines: The patient should provide information to the doctor or pharmacist about medicines they are taking, have taken recently, or plan to take in the future, including over-the-counter medicines. The effectiveness of Nimenrix may be reduced if the patient is taking medications that affect the immune system. In patients from 1 year of age, Nimenrix can be used with the following vaccines: Hepatitis A and B vaccine, measles-mumps-rubella (MMR) vaccine, measles-mumps-rubella-varicella (MMRV) vaccine, 10-valent pneumococcal conjugate vaccine, and non-adjuvanted seasonal influenza vaccine. In the second year of life, Nimenrix can also be used with diphtheria-tetanus-acellular pertussis vaccine (DTaP), including in combination with diphtheria-tetanus-acellular pertussis and hepatitis B, inactivated poliovirus, or Haemophilus influenza type b vaccines, such as DTaP-HBV-IPVHib vaccine. Also with the 13-valent pneumococcal conjugate vaccine.